Free Trial
NASDAQ:PGNX

Progenics Pharmaceuticals (PGNX) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$3.94
$4.79
50-Day Range
$4.10
$4.10
52-Week Range
$1.89
$6.37
Volume
34.93 million shs
Average Volume
1.16 million shs
Market Capitalization
$355.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
PGNX stock logo

About Progenics Pharmaceuticals Stock (NASDAQ:PGNX)

Progenics Pharmaceuticals, Inc., an oncology company, develops, manufactures, and commercializes pharmaceutical products and other technologies to target, diagnose, and treat cancer cancer in the United States and internationally. The company's product candidates include Azedra, a radiotherapeutic product candidate for the treatment of iobenguane scan positive, unresectable, and locally advanced or metastatic pheochromocytoma or paraganglioma for adult and pediatric patients; PyL, a clinical-stage fluorinated prostate specific membrane antigen (PSMA)-targeted PET/CT imaging agent for prostate cancer; and 1095, a PSMA-targeted Iodine-131 labeled small molecule, which is in Phase II clinical trial for the treatment of metastatic castration-resistant prostate cancer. Its product candidates also comprise PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic that is in Phase I clinical trial for treatment of metastatic prostate cancer; and Leronlimab, a humanized monoclonal antibody, which is in Phase III development for the treatment of HIV infection. The company also offers Relistor-subcutaneous injection for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain or advanced-illness adult patients; Relistor tablets for the treatment of OIC in adults with chronic non-cancer pain; PSMA AI, an imaging analysis technology that uses artificial intelligence and machine learning to quantify and automate the reading of PSMA targeted imaging; and automated bone scan index, a software that quantifies the hotspots on bone scans and calculates the bone scan index value. It has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of Relistor worldwide; and Amgen Fremont, Inc. to use its XenoMouse technology for generating human antibodies to PSMA. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in New York City, New York.

PGNX Stock News Headlines

PGNX_old Historical Data
Investing in Pharmaceutical Stocks
Forecaster with 99.8% Accuracy Makes Shocking Prediction
Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.
I've Got an Options Bandage for a Sick Economy
Forecaster with 99.8% Accuracy Makes Shocking Prediction
Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.
What Falling Estimates & Price Mean for Progenics (PGNX)
See More Headlines
Receive PGNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Progenics Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/07/2020
Today
7/25/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:PGNX
CUSIP
74318710
Fax
N/A
Employees
79
Year Founded
N/A

Profitability

Net Income
$-68,550,000.00
Net Margins
-180.28%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$34.99 million
Book Value
$0.54 per share

Miscellaneous

Free Float
N/A
Market Cap
$355.05 million
Optionable
Optionable
Beta
1.89
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Mark R. Baker (Age 64)
    CEO & Director
  • Mr. Patrick Fabbio (Age 51)
    Exec. VP & CFO
  • Mr. Benedict Osorio (Age 62)
    Chief Operating Officer
  • Dr. Vivien Wong (Age 62)
    Exec. VP of Devel.
  • Mr. Bryce V. Tenbarge (Age 46)
    Sr. VP of Commercial

PGNX Stock Analysis - Frequently Asked Questions

How were Progenics Pharmaceuticals' earnings last quarter?

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) released its quarterly earnings data on Thursday, May, 7th. The biotechnology company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.03. The biotechnology company earned $6.25 million during the quarter. Progenics Pharmaceuticals had a negative trailing twelve-month return on equity of 129.46% and a negative net margin of 180.28%.
Read the conference call transcript
.

What other stocks do shareholders of Progenics Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Progenics Pharmaceuticals investors own include Vonage (VG), Synergy Pharmaceuticals (SGYP), Exelixis (EXEL), Caterpillar (CAT), IMAX (IMAX), Novavax (NVAX) and Cara Therapeutics (CARA).

This page (NASDAQ:PGNX) was last updated on 7/25/2024 by MarketBeat.com Staff

From Our Partners